AC Immune shares are trading higher after the company received FDA fast track designation for anti-amyloid-beta active immunotherapy, ACI-24.060 for Alzheimer's disease
Portfolio Pulse from Benzinga Newsdesk
AC Immune's stock is trading higher after the FDA granted fast track designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, for Alzheimer's disease.
June 27, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AC Immune shares are trading higher after receiving FDA fast track designation for its Alzheimer's disease immunotherapy, ACI-24.060.
The FDA fast track designation for ACI-24.060 is a positive development for AC Immune, as it accelerates the regulatory review process and increases the likelihood of approval. This news is likely to boost investor confidence in the company and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100